Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study.

Zwaan, Christian M

Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. [electronic resource] - British journal of haematology Mar 2010 - 768-76 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

1365-2141

10.1111/j.1365-2141.2009.08011.x doi


Adolescent
Aminoglycosides--adverse effects
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Antineoplastic Agents--adverse effects
Child
Child, Preschool
Drug Administration Schedule
Female
Gemtuzumab
Humans
Infant
Leukemia, Myeloid, Acute--drug therapy
Male
Recurrence
Survival Analysis